Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A., Wang, Xuewei, Riggs, Daniel L., Porter, Brooke, Ahmann, Jonathan M., de Campos, Cecilia Bonolo, Braggio, Esteban, Bergsagel, P. Leif, Stewart, A. Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766/
https://www.ncbi.nlm.nih.gov/pubmed/30741931
http://dx.doi.org/10.1038/s41408-019-0173-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766/
https://www.ncbi.nlm.nih.gov/pubmed/30741931
http://dx.doi.org/10.1038/s41408-019-0173-0

Ejemplares similares